LAB - Standard BioTools Inc. Stock Price, Fair Value and News

2.57USD+0.07 (+2.80%)Market Closed

Market Summary

USD2.57+0.07

Market Closed

2.80%

LAB Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

LAB Stock Price

View Fullscreen

LAB RSI Chart

LAB Valuation

Market Cap

956.4M

Price/Earnings (Trailing)

-10.63

Price/Sales (Trailing)

7.54

EV/EBITDA

-8.47

Price/Free Cashflow

-9.58

LAB Price/Sales (Trailing)

LAB Profitability

EBT Margin

-70.73%

Return on Equity

-15.58%

Return on Assets

-11.57%

Free Cashflow Yield

-10.44%

LAB Fundamentals

LAB Revenue

Revenue (TTM)

126.8M

Rev. Growth (Yr)

81.3%

Rev. Growth (Qtr)

61.56%

LAB Earnings

Earnings (TTM)

-90.0M

Earnings Growth (Yr)

-90.92%

Earnings Growth (Qtr)

-62.61%

Breaking Down LAB Revenue

Last 7 days

7.1%

Last 30 days

-1.5%

Trailing 12 Months

17.6%

How does LAB drawdown profile look like?

LAB Financial Health

Current Ratio

4.5

Debt/Equity

5e-4

Debt/Cashflow

-325.34

LAB Investor Care

Shares Dilution (1Y)

374.76%

Diluted EPS (TTM)

-1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	126.8M	0	0	0
2023	96.6M	105.5M	105.2M	106.3M
2022	124.3M	112.0M	109.2M	97.9M
2021	143.3M	148.3M	136.9M	130.6M
2020	114.7M	112.6M	126.0M	138.1M
2019	117.8M	119.6M	117.1M	117.2M
2018	101.7M	104.2M	108.4M	113.0M
2017	101.0M	96.7M	99.3M	101.9M
2016	117.0M	116.5M	110.1M	104.4M
2015	117.5M	118.5M	117.5M	114.7M
2014	82.4M	92.5M	103.8M	116.5M
2013	55.9M	60.5M	66.0M	71.2M
2012	45.1M	47.5M	49.7M	52.3M
2011	35.5M	38.1M	40.2M	42.9M
2010	0	28.1M	30.8M	33.6M
2009	0	0	0	25.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Standard BioTools Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	egholm michael	sold (taxes)	-277,948	2.71	-102,564	president & ceo
Apr 05, 2024	kim hanjoon alex	acquired	-	-	70,702	chief operating officer
Apr 05, 2024	egholm michael	acquired	-	-	212,126	president & ceo
Apr 04, 2024	egholm michael	acquired	-	-	196,512	president & ceo
Apr 04, 2024	kim hanjoon alex	acquired	-	-	70,183	chief operating officer
Mar 18, 2024	casdin partners master fund, l.p.	acquired	127,780,000	2.75	46,465,500	-
Mar 05, 2024	casdin partners master fund, l.p.	bought	3,668	2.615	1,403	-
Mar 04, 2024	casdin partners master fund, l.p.	bought	642,500	2.57	250,000	-
Feb 20, 2024	casdin eli	acquired	57,000	2.5	22,800	-
Jan 05, 2024	casdin eli	acquired	-	-	7,614	-

Which funds bought or sold LAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	FourWorld Capital Management LLC	new	-	248,507	248,507	0.16%
May 16, 2024	COMERICA BANK	added	9.3	960	3,787	-%
May 16, 2024	JANE STREET GROUP, LLC	added	337	3,051,570	3,749,820	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	new	-	528,789	528,789	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	872	35,685,200	38,951,400	0.02%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-18.69	-131	43,967	-%
May 15, 2024	Redmile Group, LLC	new	-	1,115,520	1,115,520	0.04%
May 15, 2024	Mariner, LLC	new	-	64,032	64,032	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2,354	8,587,430	8,882,600	-%
May 15, 2024	Magnetar Financial LLC	new	-	4,106,710	4,106,710	0.09%

Are Funds Buying or Selling LAB?

Are funds buying LAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LAB

No. of Funds

Unveiling Standard BioTools Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 20, 2024	casdin capital, llc	16.19%	61,907,605	SC 13D/A
Mar 20, 2024	viking global investors lp	15.3%	58,651,170	SC 13G/A
Feb 26, 2024	millennium management llc	5.2%	15,037,065	SC 13G
Feb 14, 2024	indaba capital management, l.p.	9.9%	7,975,374	SC 13G/A
Feb 13, 2024	vanguard group inc	5.21%	4,133,939	SC 13G
Jan 12, 2024	neuberger berman group llc	1.51%	4,382,584	SC 13D/A
Jan 09, 2024	casdin capital, llc	16.17%	52,773,091	SC 13D/A
Jan 09, 2024	viking global investors lp	9.5%	29,106,365	SC 13G
Jan 08, 2024	caligan partners lp	2.4%	7,042,413	SC 13D/A
Nov 22, 2023	viking global investors lp	9.5%	8,289,116	SC 13D/A

Recent SEC filings of Standard BioTools Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 10, 2024	PREC14A	PREC14A
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Apr 25, 2024	8-K	Current Report
Apr 09, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading

Standard BioTools Inc. News

Latest updates

Standard BioTools Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	61.6%	45,540,000	28,188,000	25,367,000	27,666,000	25,119,000	27,021,000	25,646,000	18,777,000	26,504,000	38,265,000	28,504,000	31,018,000	32,794,000	44,608,000	39,861,000	26,058,000	27,617,000	32,440,000	26,496,000	28,196,000	30,111,000
Gross Profit	80.7%	24,188,000	13,385,000	11,154,000	13,602,000	12,281,000	11,167,000	9,220,000	4,427,000	-	-	-	-	-	-	-	-	-	17,888,000	14,038,000	15,363,000	16,990,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27,854,000	29,999,000	31,196,000
Operating Expenses	197.6%	84,370,000	28,352,000	32,326,000	31,051,000	41,712,000	25,145,500	38,247,000	42,990,000	54,007,000	49,524,000	48,116,000	48,286,000	52,114,000	61,512,000	45,325,000	39,784,000	42,559,000	41,621,000	40,312,000	42,832,000	44,317,000
S&GA Expenses	125.2%	46,943,000	20,847,500	22,292,000	22,600,000	22,308,000	17,605,000	26,340,000	30,084,000	30,875,000	22,960,000	24,072,000	24,248,000	27,608,000	31,935,000	22,655,000	20,616,000	22,695,000	18,791,000	20,729,000	22,134,000	22,824,000
R&D Expenses	130.0%	15,980,000	6,947,000	6,370,000	6,184,000	6,409,000	7,425,000	8,486,000	12,606,000	8,865,000	8,541,000	9,209,000	9,441,000	10,753,000	11,186,000	8,128,000	8,448,000	8,699,000	8,278,000	7,125,000	7,865,000	8,372,000
EBITDA Margin	-0.8%	-0.62	-0.62	-0.63	-0.72	-1.29	-1.89	-1.60	-1.43	-0.90	-0.43	-0.46	-0.36	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	1,098,000	1,223,000	1,129,000	1,117,000	1,190,000	1,049,000	1,062,000	1,030,000	1,072,000	968,000	896,000	887,000	890,000	885,000	897,000	900,000	643,000	444,000	491,000	2,701,000
Income Taxes	157.8%	100,000	-173,000	50,000	300,000	300,000	70,000	-713,000	-1,613,000	-574,000	-818,500	-1,400,000	-500,000	-1,700,000	981,500	-200,000	-1,145,000	-680,000	354,000	-1,168,000	-1,143,000	42,000
Earnings Before Taxes	-60.6%	-32,029,000	-19,938,000	-20,947,000	-16,739,000	-16,580,000	-20,775,000	-30,139,000	-65,152,000	-76,862,000	-10,243,000	-15,265,000	-17,660,000	-20,492,000	-17,039,000	-6,242,000	-14,160,000	-16,660,000	-12,331,000	-14,055,000	-14,896,000	-25,423,000
EBT Margin	-1.4%	-0.71	-0.70	-0.71	-0.80	-1.37	-1.97	-1.67	-1.50	-0.97	-0.49	-0.51	-0.41	-	-	-	-	-	-	-	-	-
Net Income	-62.6%	-32,157,000	-19,776,000	-20,997,000	-17,040,000	-16,843,000	-20,845,000	-29,426,000	-63,539,000	-76,288,000	-9,429,500	-13,843,000	-17,143,000	-18,821,000	-18,026,000	-5,999,000	-13,015,000	-15,980,000	-12,685,000	-12,887,000	-13,753,000	-25,465,000
Net Income Margin	-1.1%	-0.71	-0.70	-0.72	-0.80	-1.35	-1.94	-1.64	-1.46	-0.94	-0.45	-0.50	-0.40	-	-	-	-	-	-	-	-	-
Free Cashflow	-347.4%	-63,257,000	-14,139,000	-12,317,000	-10,167,000	-9,495,000	-19,936,000	-25,875,000	-30,926,000	-16,458,000	-7,465,000	-11,200,000	-18,836,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	140.7%	778	323	339	356	372	390	415	441	272	275	282	289	305	325	323	282	290	265	269	284	291
Current Assets	246.1%	548	158	171	183	195	209	229	251	73.00	72.00	73.00	78.00	96.00	118	123	78.00	82.00	96.00	97.00	107	111
Cash Equivalents	457.7%	288	52.00	80.00	142	114	81.00	61.00	75.00	31.00	29.00	30.00	32.00	51.00	70.00	73.00	44.00	36.00	24.00	28.00	26.00	66.00
Inventory	96.6%	40.00	21.00	22.00	22.00	23.00	21.00	22.00	23.00	23.00	21.00	24.00	25.00	22.00	20.00	20.00	19.00	16.00	14.00	15.00	14.00	14.00
Net PPE	85.2%	45.00	24.00	25.00	25.00	25.00	26.00	27.00	27.00	28.00	28.00	29.00	28.00	24.00	18.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Goodwill	0.0%	106	106	106	106	106	106	106	106	106	106	106	106	106	107	106	106	2.00	104	104	104	104
Liabilities	25.3%	200	160	160	158	158	161	166	167	250	181	183	180	182	186	171	150	149	111	107	111	109
Current Liabilities	11.2%	122	109	52.00	47.00	44.00	43.00	46.00	43.00	47.00	50.00	47.00	53.00	54.00	54.00	43.00	38.00	35.00	33.00	33.00	37.00	34.00
Long Term Debt	-47.5%	0.00	1.00	-	-	-	55.00	-	-	36.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	0.2%	55.00	55.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	1.00	-	-	-	55.00	-	-	36.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	489.9%	577	-148	-	-	-97.15	-81.47	-	-	22.00	95.00	99.00	109	123	139	152	133	141	154	163	173	182
Retained Earnings	-7.8%	-1,078	-1,000	-980	-959	-942	-926	-905	-875	-812	-736	-726	-712	-695	-676	-658	-652	-639	-623	-610	-598	-584
Additional Paid-In Capital	94.5%	1,675	861	857	853	850	847	845	841	835	831	827	822	819	816	811	786	782	778	774	771	767
Shares Outstanding	372.2%	379	80.00	79.00	79.00	79.00	79.00	78.00	77.00	77.00	77.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	133	-	-	-	126	-	-	-	464	-	-	-	282	-	-	-	847	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-344.3%	-62,476	-14,061	-11,412	-9,329	-8,485	-19,181	-24,611	-29,988	-15,590	-7,002	-9,494	-14,664	-12,901	-3,733	-4,599	-2,790	-4,295	-5,519	-4,548	-5,013	-20,130
Share Based Compensation	234.1%	11,611	3,475	3,386	3,114	3,148	1,681	4,494	4,663	4,042	4,363	4,320	3,741	3,677	4,093	4,358	3,634	2,366	3,101	3,029	2,992	2,271
Cashflow From Investing	2524.9%	318,075	-13,117	-49,926	40,126	43,154	40,245	10,736	-138,240	-868	-1,145	-1,706	-4,172	-4,923	-822	13,211	10,126	17,460	-551	6,549	-35,542	-9,757
Cashflow From Financing	-1867.4%	-19,733	-1,003	-1,164	-2,084	-2,558	-270	-5.00	212,958	18,075	7,297	9,821	-133	-1,026	432	20,417	511	-503	1,784	-181	1,040	147
Buy Backs	6828.5%	11,051	160	400	2,375	2,466	563	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LAB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 45,540	$ 25,119
Cost of revenue:
Total cost of revenue	21,352	12,838
Gross profit	24,188	12,281
Operating expenses:
Research and development	15,980	6,429
Selling, general and administrative	46,943	21,295
Restructuring and related charges	4,284	1,150
Transaction-related expenses	17,163	0
Total operating expenses	84,370	28,874
Loss from operations	(60,182)	(16,593)
Bargain purchase gain	25,213
Interest income, net	5,174	72
Other expense, net	(2,234)	(59)
Loss before income taxes	(32,029)	(16,580)
Income tax expense	(128)	(263)
Net loss	(32,157)	(16,843)
Induced conversion of redeemable preferred stock	(46,014)	0
Net loss attributable to common stockholders	$ (78,171)	$ (16,843)
Net loss per share, basic (in dollars per share)	$ (0.27)	$ (0.21)
Net loss per share, diluted (in dollars per share)	$ (0.27)	$ (0.21)
Shares used in computing net loss per share attributable to common stockholders, basic (in shares)	294,125	79,080
Shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	294,125	79,080
Product revenue
Revenue:
Total revenue	$ 23,592	$ 17,438
Cost of revenue:
Total cost of revenue	12,781	9,990
Service revenue
Revenue:
Total revenue	21,027	6,881
Cost of revenue:
Total cost of revenue	8,509	2,792
Collaboration and other revenue
Revenue:
Total revenue	921	800
Cost of revenue:
Total cost of revenue	$ 62	$ 56

LAB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 287,057	$ 51,704
Short-term investments	175,225	63,191
Accounts receivable, net	36,012	19,660
Inventories, net	40,359	20,533
Prepaid expenses and other current assets	8,912	3,127
Total current assets	547,565	158,215
Inventory, non-current	13,262	0
Royalty receivable, non-current	4,352	0
Property and equipment, net	44,786	24,187
Operating lease right-of-use asset, net	32,966	30,663
Other non-current assets	3,673	2,285
Acquired intangible assets, net	24,794	1,400
Goodwill	106,269	106,317
Total assets	777,667	323,067
Current liabilities:
Accounts payable	13,141	9,236
Accrued liabilities	30,430	21,019
Operating lease liabilities, current	5,834	4,323
Deferred revenue, current	13,906	11,607
Deferred grant income, current	3,587	3,612
Term loan, current	0
Convertible notes, current	54,656	54,530
Total current liabilities	121,554	109,327
Convertible notes, non-current	299	569
Term loan, non-current	0	3,414
Deferred tax liability	841	841
Operating lease liabilities, non-current	31,108	30,374
Deferred revenue, non-current	33,854	3,520
Deferred grant income, non-current	9,875	10,755
Other non-current liabilities	2,820	1,065
Total liabilities	200,351	159,865
Commitments and contingencies (Note 8)
Mezzanine equity:
Redeemable preferred stock: $0.001 par value; zero and 256 shares authorized at March 31, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and $255,559 at March 31, 2024 and December 31, 2023, respectively	0	311,253
Stockholders' equity (deficit):
Preferred stock: $0.001 par value, 10,000 and 9,744 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock: $0.001 par value, 600,000 shares authorized at March 31, 2024 and 400,000 shares authorized at December 31, 2023; 387,652 and 83,364 shares issued at March 31, 2024 and December 31, 2023, respectively; 380,400 and 80,232 shares outstanding at March 31, 2024 and December 31, 2023, respectively	387	83
Additional paid-in capital	1,674,672	860,816
Accumulated other comprehensive loss	(1,792)	(2,221)
Accumulated deficit	(1,078,923)	(1,000,752)
Treasury stock at cost: 7,251 and 3,132 shares at March 31, 2024 and December 31, 2023, respectively	(17,028)	(5,977)
Total stockholders' equity (deficit)	577,316	(148,051)
Total liabilities, mezzanine equity and stockholders' equity (deficit)	$ 777,667	$ 323,067

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

CEO	Dr. Michael Egholm Ph.D.
WEBSITE	fluidigm.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	523

Standard BioTools Inc. Frequently Asked Questions

What is the ticker symbol for Standard BioTools Inc.? What does LAB stand for in stocks?

LAB is the stock ticker symbol of Standard BioTools Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Standard BioTools Inc. (LAB)?

As of Fri May 17 2024, market cap of Standard BioTools Inc. is 956.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers. The fair value of Standard BioTools Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Standard BioTools Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Standard BioTools Inc. a good stock to buy?

The fair value guage provides a quick view whether LAB is over valued or under valued. Whether Standard BioTools Inc. is cheap or expensive depends on the assumptions which impact Standard BioTools Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LAB.

What is Standard BioTools Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LAB's PE ratio (Price to Earnings) is -10.63 and Price to Sales (PS) ratio is 7.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Standard BioTools Inc.'s stock?

In the past 10 years, Standard BioTools Inc. has provided -0.211 (multiply by 100 for percentage) rate of return.